Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX13 vs. Yervoy in unresectable hepatocellular carcinoma
NCT07176650Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX13 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Henlius. Primary endpoints: Area under the serum concentration-time curve from time 0 to 21 days and Area under the serum concentration-time curve within a dosing interval at steady-state at 20 weeks. Started Nov 2025; status: recruiting.
02
Drugs
HLX13
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07176650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176650.